Cancer-related cognitive changes during chemotherapy may be less inevitable than previously assumed, with baseline fitness levels emerging as a potential protective factor. The cognitive domains most vulnerable to treatment effects—and those that remain resilient—are becoming clearer through carefully controlled research tracking patients throughout their treatment journey.
This five-month prospective study followed 32 breast cancer patients through chemotherapy cycles alongside 23 age-matched healthy controls, using standardized cognitive assessments covering episodic memory, working memory, language processing, and verbal learning. Higher baseline cardiorespiratory fitness, measured through six-minute walk performance, correlated with superior verbal learning capabilities regardless of treatment status. Surprisingly, episodic memory actually improved across both groups during the study period, suggesting learning effects or adaptive responses that transcend chemotherapy exposure.
While the fitness-cognition link has been extensively documented in healthy aging populations, this research extends those protective mechanisms into active cancer treatment—a considerably more challenging physiological environment. The finding challenges the narrative that cognitive decline during chemotherapy is uniformly inevitable, suggesting instead that pre-treatment fitness reserves may create cognitive resilience buffers. However, the study's modest sample size and relatively short follow-up period limit broader conclusions about long-term cognitive trajectories. The research also raises questions about whether fitness interventions initiated before chemotherapy could meaningfully alter cognitive outcomes—a hypothesis that warrants investigation given the growing emphasis on prehabilitation in cancer care. For patients facing treatment, these results suggest that maintaining or building cardiovascular capacity before chemotherapy may offer neurological as well as physical benefits.